OpGen, which provides genetic tests that identify patients with multi-drug resistant bacterial infections, filed on Tuesday with the SEC to raise up to $35 million in an initial public offering. The genetic testing space has recently seen heightened IPO...read more
Fluidigm, which makes high-throughput sequencing devices and consumables for genetic labs, will see its quiet period end on Monday, March 21. On February 9, the company raised $75 million by offering 5.6 million shares at $13.50, at the low end of the range of...read more
Fluidigm, which makes high-throughput sequencing devices and consumables for genetic labs, raised $75 million by offering 5.6 million shares at $13.50, at the low end of the range of $13.50 to $15.50. The company had originally expected to sell 5.2 million...read more
Fluidigm, which makes high-throughput sequencing devices for genetic labs, announced terms for its IPO on Friday. The South San Francisco, CA-based company plans to raise $75 million by offering 5.2 million shares at a price range of $13.50-$15.50. At the...read more
Open season for genetic testing: OpGen files for a $35 million IPO
OpGen, which provides genetic tests that identify patients with multi-drug resistant bacterial infections, filed on Tuesday with the SEC to raise up to $35 million in an initial public offering. The genetic testing space has recently seen heightened IPO...read more
Fluidigm quiet period ends March 21
Fluidigm, which makes high-throughput sequencing devices and consumables for genetic labs, will see its quiet period end on Monday, March 21. On February 9, the company raised $75 million by offering 5.6 million shares at $13.50, at the low end of the range of...read more
Fluidigm prices upsized IPO at $13.50, the low end of the range
Fluidigm, which makes high-throughput sequencing devices and consumables for genetic labs, raised $75 million by offering 5.6 million shares at $13.50, at the low end of the range of $13.50 to $15.50. The company had originally expected to sell 5.2 million...read more
Fluidigm sets terms for $75 million IPO
Fluidigm, which makes high-throughput sequencing devices for genetic labs, announced terms for its IPO on Friday. The South San Francisco, CA-based company plans to raise $75 million by offering 5.2 million shares at a price range of $13.50-$15.50. At the...read more